Important Information for ICON plc Shareholders: Rosen Law Firm Reminds Investors of the Deadline to Join a Securities Class Action
New York, NY, March 09, 2025 – The Rosen Law Firm, a global investor rights law firm, reminds purchasers of ICON plc (NASDAQ: ICLR) ordinary shares between July 27, 2023, and October 23, 2024, both dates inclusive (the “Class Period”), of the important April 11, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for ICON plc investors under the Securities Exchange Act of 1934.
Background:
ICON plc is a global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. The Company’s services include clinical research, biotechnology services, and commercialization services. ICON plc is headquartered in Dublin, Ireland.
Allegations:
The complaint alleges that during the Class Period, ICON plc made materially false and/or misleading statements and/or failed to disclose that:
- ICON plc had inadequate internal controls over financial reporting;
- ICON plc’s revenue growth was due in part to improper revenue recognition;
- ICON plc’s financial statements were materially misstated;
- ICON plc failed to disclose related party transactions;
- ICON plc’s financial results were subject to increased scrutiny from regulatory authorities.
As a result of these allegations, the price of ICON plc’s ordinary shares was artificially inflated during the Class Period, causing investors harm.
What This Means for ICON plc Shareholders:
If you are an ICON plc shareholder who purchased ordinary shares during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is April 11, 2025. To obtain additional information, you may contact the Rosen Law Firm by calling Phillip Kim, Esq. or Zachary Halper, Esq. at 212-686-1060 or via email at [email protected] or [email protected]. You may also visit the firm’s website at
Impact on the World:
The allegations against ICON plc, if proven true, could have far-reaching consequences for the pharmaceutical industry as a whole. The Company’s services are essential to bringing new drugs and medical devices to market, and any reputational damage or regulatory scrutiny could impact investor confidence and the industry’s ability to innovate and grow.
Conclusion:
If you are an ICON plc shareholder, it is important that you take action now and contact the Rosen Law Firm to discuss your legal options. The lead plaintiff deadline is quickly approaching, and time may be running out. The Rosen Law Firm is dedicated to ensuring that all investors have the opportunity to seek justice and recover any losses they may have suffered as a result of ICON plc’s alleged securities law violations.
This is not a solicitation or an offer to buy securities, and it is not intended to provide and should not be taken as legal advice on individual matters. Rosen Law Firm represents investors worldwide, and the firm’s securities litigation expertise includes a focus on securities class actions.
The Rosen Law Firm encourages investors to be aware of the potential risks associated with investing in securities of companies engaged in pharmaceutical research and development. Investors should carefully consider the risks and potential losses before investing in any stock.
Contact Information:
Phillip Kim, Esq. or Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected] or [email protected]
Web:
